title: Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.
abstract: OBJECTIVE
  To investigate the potential clinical benefit of a combination therapy.
  
  
  METHODS
  205 patients fulfilling the ACR criteria for rheumatoid arthritis (RA), not treated with disease modifying antirheumatoid drugs previously, with an early (< or = 1 year duration), active (Disease Activity Score (DAS) > 3.0), rheumatoid factor and/or HLA DR 1/4 positive disease were randomised between sulphasalazine (SASP) 2000 (maximum 3000) mg daily (n = 68), or methotrexate (MTX) 7.5 (maximum 15) mg weekly (n = 69) or the combination (SASP + MTX) of both (n = 68).
  
  
  RESULTS
  The mean changes in the DAS during the one year follow up of the study was -1.15, -0.87, -1.26 in the SASP, MTX, and SASP + MTX group respectively (p = 0.019). However, there was no statistically significant difference in terms of either EULAR good responders 34%, 38%, 38% or ACR criteria responders 59%, 59%, 65% in the SASP, MTX, and SASP + MTX group respectively. Radiological progression evaluated by the modified Sharp score was very modest in the three groups: mean changes in erosion score: +2.4, +2.4, +1.9, in narrowing score: +2.3, +2.1, +1.6 and in total damage score: +4.6, +4.5, +3.5, in the SASP, MTX, and SASP + MTX groups respectively. Adverse events occurred more frequently in the SASP + MTX group 91% versus 75% in the SASP and MTX group (p = 0.025). Nausea was the most frequent side effect: 32%, 23%, 49% in the SASP, MTX, and SASP + MTX groups respectively (p = 0.007).
  
  
  CONCLUSIONS
  This study suggests that an early initiation therapy of disease modifying drug seems to be of benefit. However, this study was unable to demonstrate a clinically relevant superiority of the combination therapy although several outcomes were in favour of this observation. The tolerability of the three treatment modalities seems acceptable.
authors.affiliation: Institut de Rhumatologie, Hardy B, Hôpital Cochin, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: B
authors.initials: B
authors.lastname: Combe
authors.forename: A
authors.initials: A
authors.lastname: Cantagrel
authors.forename: P
authors.initials: P
authors.lastname: Goupille
authors.forename: P
authors.initials: P
authors.lastname: Olive
authors.forename: M
authors.initials: M
authors.lastname: Schattenkirchner
authors.forename: S
authors.initials: S
authors.lastname: Meusser
authors.forename: L
authors.initials: L
authors.lastname: Paimela
authors.forename: R
authors.initials: R
authors.lastname: Rau
authors.forename: H
authors.initials: H
authors.lastname: Zeidler
authors.forename: M
authors.initials: M
authors.lastname: Leirisalo-Repo
authors.forename: K
authors.initials: K
authors.lastname: Peldan
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018501:Antirheumatic Agents; D012460:Sulfasalazine; D008727:Methotrexate